All In MedTech

Device Trial Radar · NCT02378844

A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic Migraine

A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine

Last checked: Nov 19, 2026Latest source record: Aug 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 477 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

477

Actual

Start

Jun 2015

Primary completion

Feb 1, 2018

Study completion Aug 29, 2018

Sponsor

Lead sponsor
ElectroCore INCNot on our public-company list
Sponsor type
Industry
First posted
Mar 4, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, double-blind, randomized, sham-controlled, multicentre investigation.

Conditions

  • Migraine

Interventions

  • gammaCore®-RDevice

    Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

  • gammaCore®-R ShamDevice

    Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Number of Migraine DaysTime frame: last 4 weeks of the randomized/controlled period compared to the subject's own 4-week run-in period.

Locations

22 sites in 8 countries. Site status is shown where the registry gives one.

  • Neurology Department, University of Liège

    Liège, Belgium

  • Danish Headache Center

    Glostrup Municipality, Denmark

  • Neurologische Klinik und Poliklinik, Charité Campus Mitte

    Berlin, Germany

19 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.